2024年7月30日 · It is known that CCS and ASPS have a common biological feature of melanoma and Xp11.2/TFE3 translocation renal cell carcinoma, and immune-checkpoint inhibitors (ICIs) are effective in these tumors. The authors conducted a phase 2 trial to evaluate the efficacy and safety of nivolumab for CCS and ASPS.

2023年4月7日 · Alveolar soft part sarcoma (ASPS) is a soft part malignancy affecting adolescents and young adults. ASPS is characterized by a highly integrated vascular network, and its high metastatic potential indicates the importance of ASPS’s prominent angiogenic activity.

2023年11月27日 · Conventional cytotoxic drugs are not effective in alveolar soft-part sarcoma (ASPS). Immune checkpoint (programmed cell death protein 1/programmed death-ligand 1) inhibitors (ICIs) are promising drugs in ASPS. A worldwide registry explored the efficacy of …

2025年2月20日 · LMS emerged as the most common subtype (231 patients, 20.3 %), followed by ASPS (168 patients, 14.7 %), and UPS (162 patients, 14.2 %). LPS was also frequently observed, comprising 159 patients (13.9 %), including subtypes such as dedifferentiated liposarcoma (DDLPS) with 62 patients (5.4 %).

在软组织肉瘤中有一类非常罕见的肉瘤即腺泡状软组织肉瘤（alveolar soft part sarcoma，ASPS)，其发病率仅占软组织肉瘤的0.5%-1%。 好发于15 ～ 35岁的青年女性，以四肢深部软组织内多见，因肿块生长缓慢，无临床症…

Alveolar soft part sarcoma (ASPS) is a rare form of soft tissue sarcoma and is most often seen in adolescents and young adults. Despite its unique histology and well-characterised genetic translocation, many questions remain regarding the pathogenesis and …

腺泡状软组织肉瘤（ASPS）是一种好发于年轻女性的罕见病。 2022年12月9日，美国食品和药品监督管理局（FDA）批准 阿替利珠单抗（Atezolizumab）用于患有无法切除或转移性腺泡状软组织肉瘤（ASPS）的成人和儿童患者…

2020年12月15日 · Patients with alveolar soft part sarcoma (ASPS) are rare and have few treatment options. We assessed the activity of geptanolimab (GB226), a fully humanized programmed cell death protein 1 antibody, for patients with unresectable, recurrent, or …

2024年7月30日 · It is known that CCS and ASPS have a common biological feature of melanoma and Xp11.2/TFE3 translocation renal cell carcinoma, and immune-checkpoint inhibitors (ICIs) are effective in these tumors. The authors conducted a phase 2 trial to evaluate the efficacy and safety of nivolumab for CCS and ASPS. Methods

2021年7月1日 · Immune checkpoint inhibitors are active in soft-tissue sarcoma, with a 14% objective response rate (ORR) for all combinations. Responses vary by histologic subtype, …